Megace

Megestrol acetate, the active ingredient in Megace, is a progestin presented as an oral dosage form for systemic use. It is employed in the management of cancer‑related cachexia, advanced breast cancer, and endometrial cancer, providing both antineoplastic activity and appetite stimulation. It is indicated for patients experiencing severe weight loss associated with AIDS or malignancy and for hormone‑responsive tumors.

GNH USA supplies Megace as a licensed, GDP‑compliant international pharmaceutical supplier, delivering GMP‑manufactured product to hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality, regulatory compliance and reliable logistics.

Megace is a progestin hormonal therapy used in specific oncologic and cachexia contexts. - Cachexia associated with AIDS or cancer: improves appetite and promotes weight gain in patients with severe wasting. - Advanced breast cancer: provides antineoplastic effect in hormone‑responsive disease. - Endometrial cancer: used as part of hormonal treatment for disease control.

Megace may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Edema: peripheral swelling, especially in lower extremities. - Fatigue: generalized tiredness or weakness. - Increased blood glucose: hyperglycemia, particularly in diabetic patients.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Adrenal suppression: signs of cortisol deficiency. - Hormonal disturbances: menstrual irregularities or androgenic effects.

When prescribing Megace, clinicians should consider several safety measures and monitoring requirements. - Assess nutritional status: evaluate baseline weight and appetite before initiating therapy. - Monitor blood glucose: check fasting glucose regularly, especially in diabetic patients. - Observe for thrombotic risk: screen for history of clotting disorders or immobilization. - Evaluate hormonal effects: watch for menstrual changes, androgenic signs, or adrenal insufficiency. - Review concomitant medications: avoid drugs that may increase thrombotic or hyperglycemic risk. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Megace can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, increasing bleeding risk. - CYP3A4 inducers (e.g., rifampin, phenytoin): can reduce plasma concentrations of megestrol acetate, diminishing therapeutic effect. - Glucocorticoids: additive glucocorticoid activity may exacerbate hyperglycemia and adrenal suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: megestrol acetate may raise blood glucose, requiring dose adjustment of insulin or oral hypoglycemics. - Hormonal therapies (e.g., tamoxifen): potential antagonistic effects on hormone pathways. - Diuretics: may increase risk of electrolyte imbalance when combined with edema.